Prevalence of hypercortisolism in patients with difficult-to-control type 2 diabetes and cardiovascular disease: Results from CATALYST

Fonseca et al. • 2024 • WCIRDC

Read more

Prevalence of hypercortisolism in patients with difficult-to-control type 2 diabetes and high blood pressure: Results from CATALYST

Handelsman et al. • 2024 • WCIRDC

Read more

Open-label Extension Study Evaluating the Safety and Efficacy of Long-term Use of Relacorilant in Patients With Endogenous Hypercortisolism (Cushing Syndrome): Results from the First Interim Analysis

Badiu et al. • 2024 • AACE MENA 2024 Congress

Read more

Relacorilant Maintained Hypertension Improvement in Long-term Follow-up of Patients With Endogenous Hypercortisolism (Cushing Syndrome)

Gilis-Januszewska et al. • 2024 • AACE MENA 2024 Congress

Read more

Rapid Clinical Improvements in a Patient with Difficult-to-Control Type 2 Diabetes by Addressing Underlying Hypercortisolism with Mifepristone

2024 • AACE 2024

Read more

© 2025 Corcept Therapeutics, Incorporated

Privacy Notice | Terms of Use | Site Map | Your Privacy Choices | LinkedIn | Youtube

Privacy Notice

Terms of Use

Site Map

Your Privacy Choices

LinkedIn

Youtube